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E-mail address: nkgw@biochem.tohoku.ac.jp (K. NThe presence of amyloid b-peptide (Ab) in human blood has recently been established, and it has
been hypothesized that Ab readily contacts red blood cells (RBC) and oxidatively impairs RBC func-
tions. In this study, we conducted in vitro and in vivo studies, which provide evidence that Ab
induces oxidative injury to RBC by binding to them, causing RBC phospholipid peroxidation and
diminishing RBC endogenous carotenoids, especially xanthophylls. This type of damage is likely to
injure the vasculature, potentially reducing oxygen delivery to the brain and facilitating Alzheimer’s
disease (AD). As a preventive strategy, because the Ab-induced RBC damage could be attenuated by
treatment of RBC with xanthophylls, we suggest that xanthophylls may contribute to the prevention
of AD.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction modiﬁcation of hemoglobin (Hb) [7] and to impair RBC shape andAmong brain diseases, Alzheimer’s disease (AD, a neurodegen-
erative disorder) is the most common type of dementia in the el-
derly population. AD is believed to be caused by a buildup of
amyloid plaques in the brain [1], and several alterations have also
been observed in the blood. In red blood cells (RBC) of AD patients,
there is an abnormal increase of phospholipid hydroperoxides
(PLOOH), a speciﬁc marker of membrane oxidative injury [2]. Irreg-
ular distortion and rapid aging of RBC are also observed in demen-
tia patients [3,4]. These RBC alterations are therefore likely to
participate in AD pathogenesis.
On the other hand, as the presence of amyloid b-peptide (Ab) in
blood has become clearer [5], increasing attention has been paid to
the interaction between RBC and Ab (Ab42 [6], fragment of Ab [6],
and Ab ﬁbrils [7,8]) in blood circulation. Jayakumar et al. recently
reported that RBC were bound to Ab ﬁbrils when both were incu-
bated in vitro [7]. Ab binding to RBC was shown to induce oxidativechemical Societies. Published by E
loid b-peptide; avidin-FITC,
PLC, high-performance liquid
peroxide; PEOOH, phosphati-
id hydroperoxides; RBC, red
akagawa).deformability [8]. These studies [6–8] suggested that Ab toxicity
may account for the above-mentioned alterations of AD erythro-
cytes [2–4], leading to the hypothesis that Ab oxidatively impairs
RBC function (e.g., oxygen delivery to the brain), thereby poten-
tially facilitating AD. However, evidence as to whether Ab actually
induces oxidative injury to RBC is still unclear, despite one report
of in vitro Hb oxidation by Ab ﬁbrils [7]. An improved understand-
ing of Ab-induced RBC damage is needed, and in vivo evaluations
will be particularly valuable.
The aim of this study was to ascertain whether Ab induced oxi-
dative damage to RBC under in vitro and in vivo conditions. Mem-
brane oxidative injury was veriﬁed by measuring changes in the
levels of RBC PLOOH and of RBC antioxidants. Since we found that
Ab induced a marked increase in RBC PLOOH and a decrease in
carotenoids (especially polar xanthophylls), we performed a carot-
enoid supplementation study to evaluate the attenuation effect of
oxidative stress in Ab-treated RBC.2. Materials and methods
2.1. Materials
Synthetic Ab40 and Ab42 were purchased from Peptide Institute
Inc. (Osaka, Japan), and were individually biotinylated with N-
hydroxysuccinimido-biotin (Pierce, Rockford, IL) according to alsevier B.V. All rights reserved.
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nate (avidin–FITC) was obtained from Pierce. The other reagents
were of analytical or biochemical grade.
2.2. In vitro incubation experiment
Blood was collected from a healthy donor into a tube containing
EDTA-2Na as an anticoagulant and was centrifuged at 1000g for
10 min at 4 C. After plasma and buffy coat were removed, the
RBC were washed three times with PBS (pH 7.4) to prepare packed
cells. To the packed cells (200 ll), 200 ll of biotinylated Ab40 or
Ab42 (0–10 lM in PBS) was added and the cells were incubated
up to 48 h at 37 C. After incubation, the packed cells were washed
three times with PBS to remove unbound Ab.
2.3. In vivo animal study
One hundred ll of biotinylated Ab42 (100 lM in PBS) or PBS
vehicle was injected into male C57BL/6NJcl mice (13 weeks old;
Clea, Tokyo, Japan) via the tail vein. At 5 h after the injection, blood
was collected by decapitation. Packed cells were prepared from the
blood sample. These protocols were reviewed by the Committee on
the Ethics of Animal Experiments of Tohoku University, and this
experiment was carried out in accordance with the Animal Exper-
iment Guidelines of Tohoku University.
2.4. In vitro and in vivo carotenoid supplementation study
For in vitro evaluation of the effect of carotenoids on Ab-in-
duced erythrocytic damage, human packed cells (3.5 ml) were
pre-incubated with 3.5 ml of lutein, astaxanthin, or b-carotene
(20 lM, dissolved in human plasma) for 4 h at 37 C. After being
washed with PBS, the carotenoid-enriched packed cells were sub-
jected to the in vitro incubation experiment with Ab as described
above.
For in vivo evaluation, lutein (food-grade, purity of 92%; Kemin
Foods, Des Moines, IA) or astaxanthin (reagent-grade, purity of
98%; Wako, Osaka, Japan) was suspended in 100 ll of corn oil,
and C57BL/6NJcl mice (12 weeks old) orally received lutein (20
and 40 mg/kg/day), astaxanthin (40 mg/kg/day), or corn oil alone
once a day for a total of 7 successive days. During the feeding per-
iod, the mice were allowed free access to the laboratory rodent
chow and water. On day 7, biotinylated Ab42 was injected into
the mouse tail vein as described above. At 5 h after the injection,
blood was collected and packed cells were prepared.
2.5. Analysis of Ab binding to RBC
Ab-treated packed cells (10 ll) were mixed with 5 ll of avidin–
FITC (3 lg/ml in HEPES) and 50 ll of HEPES buffer (10 mM, pH 8.5),
and the mixture was incubated at 4 C for 15 min to label the bio-
tinylated Ab. After washing the packed cells with PBS, Ab binding
was evaluated using a ﬂuorescence microscope (BZ8000, Keyence,
Osaka, Japan) and a FACSCalibur ﬂow cytometer (Becton Dickinson
Immunocytometry Systems, San Jose, CA). In the ﬂow cytometric
analysis, ﬂuorescence was measured at an emission wavelength
of 530 nm with excitation at 488 nm. A total of 10 000 events were
measured for each sample.
2.6. Measurement of RBC PLOOH and antioxidants
RBC PLOOH (phosphatidylcholine hydroperoxide (PCOOH) and
phosphatidylethanolamine hydroperoxide (PEOOH)) was deter-
mined by high-performance liquid chromatography (HPLC) with
chemiluminescence detection [2,10–12]. For RBC antioxidants,
carotenoids and tocopherols were measured by HPLC with UVand mass spectrometric detection [13–16] and HPLC with ﬂuores-
cence detection [17], respectively.3. Results
3.1. Ab induces oxidative damage to RBC under in vitro and in vivo
conditions
When human packed cells were incubated with biotinylated Ab
in vitro, RBC were bound with Ab under microscope observation
(Fig. 1, left ﬁgures). Ab binding to RBC appeared to cause RBC aggre-
gation and hemolysis. In support of this conclusion, ﬂow cytometry
showed that biotinylated Ab, especially Ab42, dose- and time-
dependently adhered to RBC (Fig. 1, right ﬁgures). As shown in
Fig. 2A, it was evidenced that Ab induced oxidative damage to
RBC, as RBC PLOOH (sum of PCOOH and PEOOH) was increased up
to 6-fold in the proportion of the dose of biotinylated Ab. The effect
on RBC antioxidants was also investigated, and polar carotenoids
such as lutein were found to be susceptible to Ab toxicity (Fig. 2B).
Following these in vitro results (Figs. 1 and 2), we performed a
mouse study using biotinylated Ab42, and found that its injection
caused Ab adherence to RBC (Fig. 3A) and peroxidation of RBC
phospholipids (Fig. 3B). However, the effect on RBC carotenoids
could not be evaluated because these carotenoid levels in mouse
RBC were too low to be detected. These results strongly suggest
that Ab induces oxidative damage to RBC under in vitro and
in vivo conditions.
3.2. Polar carotenoid treatment improves resistance of RBC to Ab-
induced oxidative damage
We had become interested in the decrease of polar carotenoids
in Ab-treated RBC (Fig. 2B), and we performed a carotenoid supple-
mentation study. By incubating human packed cells with lutein,
astaxanthin, or b-carotene, carotenoid-enriched packed cells were
prepared (Fig. 4A). It was found that the carotenoid-enriched
packed cells showed a decreased interaction with biotinylated Ab
(Fig. 4B) and a reduced susceptibility to peroxidation (Fig. 4C).
The inhibitory efﬁcacy was ranked as lutein > astaxanthin > b-car-
otene, and this seemed to be correlated with the incorporated
amount of carotenoid into the RBC (Fig. 4A).
Similarly to those in vitro results, oral administration of polar
carotenoid (lutein or astaxanthin) to mice led to their increased
concentration in RBC (Fig. 5A) and to a decrease in RBC-Ab interac-
tion (Fig. 5B) and membrane oxidative injury (Fig. 5C). These re-
sults suggest that polar carotenoid treatment improves resistance
of RBC to Ab-induced oxidative damage.4. Discussion
Ab deposits in the extracellular space of the brain and on the
walls of cerebral blood vessels, particularly capillaries (microvas-
culature). From the brain, Ab is transferred into blood plasma. As
a proof of this transfer, DeMattos et al. have reported a dynamic
equilibrium between brain Ab and plasma Ab [18]. They showed
that when an anti-Ab antibody (m266) was administered peripher-
ally to PDAPP transgenic mice (AD-model mice), plasma Abwas in-
creased up to 1000-fold, indicating that brain Ab was transferred
across the blood-brain barrier to the plasma. Besides inﬂux of Ab
from the brain into blood, Ab is also produced in platelets [19].
Thus, Ab circulates in the peripheral blood, and it is likely that
Ab readily contacts RBC in the circulation, especially in AD patients.
In the present study, using biotinylated Ab, we clearly con-
ﬁrmed that RBC are capable of binding Ab in vitro as well as in vivo.
Ab42 interacted with RBCmore avidly than Ab40, as suggested by a
Fig. 1. Microscopic observation (left ﬁgures) and ﬂow cytometric analysis (right ﬁgures) of biotinylated Ab-treated RBC. Experimental procedures are described in Materials
and Methods. Values are means ± SD (n = 3).
Fig. 2. Effects of Ab on RBC PLOOH (sum of PCOOH and PEOOH) (A) and carotenoids (B). Experimental procedures are described in Materials and Methods. Values are
means ± SD (n = 3). Means without a common letter differ, P < 0.05.
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concentrations of unbound Ab42 over Ab40 in human plasma
[21]. It is conceivable that two additional hydrophobic amino acids
at the C-terminus of Ab42 increase the rate of Ab insertion into theRBC bilayer [22]. For the adherence mechanism, Ab42 is considered
to adhere to complement receptor 1 (CR1) on erythrocytes [23].
In order to supply oxygen to the brain, RBC need to deform as
they pass through the narrow pores of capillaries. However, the
Fig. 3. Effect of biotinylated Ab42 injection on mouse RBC–Ab interaction (A) and RBC PLOOH (sum of PCOOH and PEOOH) (B). Experimental procedures are described in
Materials and Methods. Values are means ± SD (n = 3). Difference is considered signiﬁcant from biotinylated Ab42-untreated control mouse (⁄P < 0.01).
Fig. 4. Effect of carotenoid-enriched packed cells (A) on RBC–Ab interaction (B) and RBC PLOOH (sum of PCOOH and PEOOH) (C). Experimental procedures are described in
Materials and Methods. Values are means ± SD (n = 3). Difference is considered signiﬁcant from carotenoid-untreated packed cells (⁄P < 0.01). Means without a common letter
differ, P < 0.05.
1252 K. Nakagawa et al. / FEBS Letters 585 (2011) 1249–1254RBC deformability is reported to be decreased when Ab adheres to
RBC [8]. Thus, the interaction of Ab with RBC may decrease the
blood ﬂow, impairing oxygen delivery to the brain and thus con-
tributing to brain hypoxia [8]. These processes are implicated in
the pathogenesis of AD. In support of these notions, a relationship
between blood Ab and AD was observed in Down syndrome pa-tients, among whom those with elevated Ab levels in plasma were
reported to have a greater risk of developing AD [24]. On the other
hand, it has been hypothesized that Ab-induced oxidative stress
may play an important role in alteration of RBC shape and mor-
phology [6,7], but evidence in support of this notion, especially
in vivo evidence, has never been provided. In this study, we pro-
Fig. 5. Effect of carotenoid (lutein or astaxanthin) administration on RBC carotenoid level (A), RBC–Ab interaction (B), and RBC PLOOH (sum of PCOOH and PEOOH) (C).
Experimental procedures are described in Materials and Methods. Values are means ± SD (n = 8). Means without a common letter differ, P < 0.05.
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verifying the Ab-associated increase in RBC PLOOH and the de-
crease in RBC carotenoids, especially lutein, under in vitro and
in vivo conditions.
Unlike RBC, neurons and their relation to Ab have been studied
thoroughly. Some of those studies reported that Ab impairs mito-
chondrial function and induces apoptosis in neuronal cells [25].
In contrast, RBC lack mitochondria and a nucleus, and they do
not undergo apoptosis. Thus, Ab damages RBC independently of
mitochondrial impairment and apoptosis induction. On the other
hand, there are studies reporting that Ab elicits neurotoxic activity
via generation of reactive oxygen species (ROS) [26]. The mecha-
nism by which Ab generates ROS is not fully understood, despite
a study implicating involvement of the methionine residue at posi-
tion 35 of Ab [27]. Considering these data, it is likely that Ab in-
duces ROS, which in turn trigger membrane oxidative injury in
RBC. Because Ab seems to cause RBC aggregation and hemolysis,
it is plausible that Ab-induced hemolysis enhances a cascade of
oxidative reactions in RBC. These reactions produce superoxide,
which dismutates to form hydrogen peroxide. Hydrogen peroxide
reacts with Fe(II) hemoglobin to produce Fe(IV) ferrylhemoglobin,
a strong oxidizing agent. These ROS cause formation and accumu-
lation of RBC PLOOH, and this could increase membrane rigidity
and decrease the deformability of RBC.
On the other hand, concerning an additional factor that contrib-
utes to impaired blood ﬂow and oxygen delivery in AD patients,
Ravi et al. reported that Ab ﬁbrils can induce adhesion of RBC to
endothelial cells [28]. The adherence of RBC to endothelium leads
to slowed blood ﬂow. Such phenomenon may be particularly pro-
nounced in the brain microvasculature with vascular amyloidosis.
In this study, to evaluate peroxidizability, we measured the
PLOOH content in RBC. Because PLOOH are the primary oxidationproducts of PL, an increase in PLOOH directly reﬂects oxidative
stress [2,10–12,29]. Carotenoid treatment, especially polar carote-
noids such as lutein and astaxanthin, clearly led to decreases in
both the RBC-Ab interaction and in RBC PLOOH formation
in vitro and in vivo. Recently, these xanthophylls (lutein and asta-
xanthin) have received increased scientiﬁc interest due to their po-
tent antioxidant activity [30] and hence their possible anti-brain
aging effect. Our results indicate that xanthophylls act as antioxi-
dants and/or reduce the binding of Ab to RBC, thereby improving
the resistance of RBC to Ab-induced oxidative damage. This may
help to prevent AD. Further studies are needed to evaluate the
effective mechanism of xanthophylls and the prospect of using
xanthophylls as an AD therapeutic agent.
There have been numerous studies to date showing the involve-
ment of oxidative stress in the pathogenesis of AD. The present
study indicates that oxidative stress can, at least in part, originate
from Ab adherence to RBC. Ab-induced erythrocytic oxidative dam-
age is likely to injure the vasculature, resulting in impaired oxygen
delivery, and this could initiate the cascade leading to AD pathol-
ogy. As a preventive strategy, we suggest that Ab-induced RBC
damage could be reduced via the use of xanthophylls. These possi-
bilities warrant testing in animal models of AD.Acknowledgements
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